Zhong Fangfang, Li Zaibo, Sun Yihua, Xiao Yaoxing, Li Juan, Zhou Xianrong, Cong Qing, Sui Long, Tao Xiang, Zhao Chengquan
Department of Pathology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.
Department of Pathology, The Ohio State University, Columbus, OH, United States.
Front Oncol. 2023 Mar 29;13:1161631. doi: 10.3389/fonc.2023.1161631. eCollection 2023.
We investigated HPV genotypes in a large cohort of patients with definitive cervical histologic diagnosis.
HPV testing was performed by real-time PCR assay, including 18 high-risk HPV (hrHPV) and 3 low-risk HPV (lrHPV). Totally 61,422 patients with documented HPV genotyping results within 6 months before cervical histologic diagnoses were included.
HrHPV positive rate was 55.1% among all tested cases with the highest in adenosquamous carcinoma (94.1%), followed by squamous cell carcinoma (SCC) (93.7%), cervical intraepithelial neoplasia 2/3 (CIN2/3) (92.8%). HrHPV positive rates were significantly higher in high-grade squamous lesions than in those in glandular lesions. HPV16 was the most common genotype followed by HPV52 and HPV58 in CIN2/3. The most frequent hrHPV genotype in adenocarcinoma (AIS) was HPV18, followed by HPV16, HPV45 and HPV52. In SCC cases, HPV16 was the most common type followed by HPV58, HPV52, HPV18 and HPV33. However, HPV18 showed significantly higher prevalence in adenocarcinoma and adenosquamous carcinoma than in that in SCC. Theoretically, the protective rates of 2/4-valent and 9-valent vaccine were 69.1% and 85.8% for cervical cancers.
The prevalence of HPV genotypes in Chinese population was different from that in Western population. Some hrHPV types were identified in cervical precancerous lesions and cancers, which are not included in current HPV vaccines. These data provide baseline knowledge for future HPV vaccine development.
我们在一大群经明确宫颈组织学诊断的患者中调查了HPV基因型。
采用实时PCR检测HPV,包括18种高危型HPV(hrHPV)和3种低危型HPV(lrHPV)。纳入了61422例在宫颈组织学诊断前6个月内有记录的HPV基因分型结果的患者。
在所有检测病例中,hrHPV阳性率为55.1%,腺鳞癌中最高(94.1%),其次是鳞状细胞癌(SCC)(93.7%)、宫颈上皮内瘤变2/3级(CIN2/3)(92.8%)。高级别鳞状病变中的hrHPV阳性率显著高于腺性病变中的阳性率。在CIN2/3中,HPV16是最常见的基因型,其次是HPV52和HPV58。腺癌(AIS)中最常见的hrHPV基因型是HPV18,其次是HPV16、HPV45和HPV52。在SCC病例中,HPV16是最常见的类型,其次是HPV58、HPV52、HPV18和HPV33。然而,HPV18在腺癌和腺鳞癌中的患病率显著高于SCC。理论上,二价/四价和九价疫苗对宫颈癌的保护率分别为69.1%和85.8%。
中国人群中HPV基因型的流行情况与西方人群不同。在宫颈癌前病变和癌症中发现了一些目前HPV疫苗未涵盖的hrHPV类型。这些数据为未来HPV疫苗的研发提供了基础信息。